Monoclonal Antibodies Market by Application and Geography - Forecast and Analysis 2021-2025

The monoclonal antibodies market share is expected to increase by USD 63.41 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 8.2%.

This monoclonal antibodies market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers monoclonal antibodies market segmentations by application (oncology, autoimmune disordersiInfectious diseases, and other applications) and geography (North America, Europe, Asia, and ROW). The monoclonal antibodies market report also offers information on several market vendors, including AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA among others.

What will the Monoclonal Antibodies Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Monoclonal Antibodies Market Size for the Forecast Period and Other Important Statistics

 

Monoclonal Antibodies Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The introduction of low-priced biosimilar monoclonal antibodies is notably driving the monoclonal antibodies market growth, although factors such as the high cost of monoclonal antibodies may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the monoclonal antibodies industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Monoclonal Antibodies Market Driver

The introduction of low-priced biosimilar monoclonal antibodies is notably driving the monoclonal antibodies market growth. The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses could be instrumental in reducing the cost of medication and increasing patient access to treatment. The reason for the low cost of a biosimilar is that the number of clinical trials for a biosimilar is comparatively lesser than that needed for the original biologic drug. Biosimilars of widely sold monoclonal antibodies INFLECTRA have already entered the market, and many are in the pipeline. Another major step to control the cost of delayed entry would be to limit patent litigation to avoid delay in market entry and to invest in physician and patient education to increase awareness about biosimilars.

Key Monoclonal Antibodies Market Trend

Increasing cases of diseases like cancer and immunological disorders is the key trend driving the monoclonal antibodies market growth. Cancer is the second major cause of death across the globe, and cancer cases have increased significantly in the past few years. This sudden increase in the cancer rate is said to have a genetic basis. The accumulation of mutant alleles in the population is responsible for such a tremendous rise in cancer cases across the globe. In addition to the genetic factors, urbanization, pollution, and lifestyle changes contribute to the rise in the incidence of cancer. The increased prevalence of cancers and immunological disorders is fueling the use and importance of monoclonal antibodies, which are among the effective treatments for such disorders. In the US, EU5, and Japan, governments issuing clear regulatory pathways and payers providing near-term growth opportunities for biologics are factors that are supporting the growth of biologics. In developing countries, the socioeconomic conditions characterized by poor financial access to high-priced biologics create non-consumption and untapped demand, hence leading to favorable long-term growth opportunities.

Key Monoclonal Antibodies Market Challenge

The major challenge impeding the monoclonal antibodies market growth is the high cost of monoclonal antibodies. Monoclonal antibodies cost high, both at the end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities. For manufacturing a monoclonal antibody, several processes, starting from the immunization and serum screening to the splenocyte fusion and single-cell cloning, are needed. For instance, the immunization stage of animals requires the availability of animal house facilities where the animals meant for immunization can be kept under hygienic conditions. The procedures of splenocyte fusion and isolation of single clones require highly skilled personnel for handling the biotechnological tools. All these processes require advanced equipment and sophisticated research procedures, which are highly expensive. As such, manufacturers incur huge expenses for the development of a single monoclonal antibody product. To recover the development costs, the manufacturers set high prices for monoclonal antibodies.

This monoclonal antibodies market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the monoclonal antibodies market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the monoclonal antibodies market during the forecast period.

Who are the Major Monoclonal Antibodies Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AbbVie Inc.
• AstraZeneca Plc
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA

 

This statistical study of the monoclonal antibodies market encompasses successful business strategies deployed by the key vendors. The monoclonal antibodies market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• AbbVie Inc. - It is adalimumab, an immunosuppressant monoclonal antibody for the treatment of Rheumatoid Arthritis, Plaque Psoriasis, Crohn's drsease, and Ulcerative colitis.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The monoclonal antibodies market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Monoclonal Antibodies Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the monoclonal antibodies market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Monoclonal Antibodies Market?

For more insights on the market share of various regions Request for a FREE sample now!

61% of the market's growth will originate from North America during the forecast period. US and Germany are the key markets for monoclonal antibodies market in North America. Market growth in this region will be faster than the growth of the market in other regions.

Some of the biologics available in North America are HUMIRA, Rituxan, and REMICADE. These products are in huge demand in the region, which will facilitate the monoclonal antibodies market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The current COVID-19 pandemic had a negative impact on the growth of the regional monoclonal antibodies market in 2020. The pandemic led to a decline in the use of monoclonal antibodies in regional healthcare facilities due to the temporary suspension of non-urgent/elective medical consultations and procedures. The pandemic also prompted patients to avoid visiting physicians unless necessary, which impeded the growth of the regional monoclonal antibodies market in 2020. However, the demand for monoclonal antibodies is likely to recover and increase after 2020-2021 due to the resumption of regular doctor visits as well as medical consultation services and treatments in North America.

What are the Revenue-generating Application Segments in the Monoclonal Antibodies Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The monoclonal antibodies market share growth by the oncology segment will be significant during the forecast period. The increasing incidences of different types of cancers, the willingness of people to pay for highly-priced monoclonal antibodies for the treatment of cancers drives the growth of this segment. Due to the lack of generic substitutes, monoclonal antibodies are sold at high rates that the manufacturers set to earn huge revenues. The growth of the market will be driven by the revenues generated by the widely sold monoclonal antibodies for cancer.

This report provides an accurate prediction of the contribution of all the segments to the growth of the monoclonal antibodies market size and actionable market insights on post COVID-19 impact on each segment.

 

Monoclonal Antibodies Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 8.2%
Market growth 2021-2025	$ 63.41 billion
Market structure	Concentrated
YoY growth (%)	7.48
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 61%
Key consumer countries	US, Germany, France, UK, and Japan
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Monoclonal Antibodies Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive monoclonal antibodies market growth during the next five years
• Precise estimation of the monoclonal antibodies market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the monoclonal antibodies industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of monoclonal antibodies market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch